Results 211 to 220 of about 195,243 (312)

Biochemical Responses of Anopheles spp. Larvae to a Novel Brazilian BR101 Bacillus thuringiensis var. israelensis Formulation: Oxidative Stress, Detoxification Enzymes, and Safety for Nontarget Notonectidae and Gerridae Aquatic Insects

Chemistry &Biodiversity, Volume 23, Issue 2, February 2026.
Bti BR101 exhibits strong larvicidal activity against Anopheles larvae spp., with dose‐dependent mortality and LC50 of 3.13 µg/mL. Bti increases ROS, lipid and protein oxidation, and activates antioxidant enzymes (SOD, CAT, GPx) and detoxification pathways (MFO and esterases), indicating moderate oxidative stress.
Izabel Cristina de Oliveira Bentes, Dayane Dantas Abensour, Maria Luiza Lima da Costa, Raquel Telles de Moreira Sampaio, Leticia Bernadete da Silva, Francisco Augusto da Silva Ferreira, Cláudia Patrícia da Silva Tavares, Hergen Vieira de Souza, Francisco de Assis Marque, Mário Antonio Navarro da Silva, Eduarda Andrade de Lima, Gislayne Trindade Vilas‐Boas, João Antonio Cyrino Zequi, André Correa de Oliveira, Rosemary Aparecida Roque   +14 more
wiley   +1 more source

Chronic Myeloid Leukemia and the T315I <i>BCR::ABL1</i> Mutation. [PDF]

Int J Mol Sci
Pierro F, Stella S, Fazio M, Russo S, Massimino M, Mirabile G, Belletti D, Allegra A, Stagno F.   +8 more
europepmc   +1 more source

A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Novartis
openalex   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients. [PDF]

Cancer Immunol Immunother
Cayssials E, Lefèvre L, Decroos A, Jacomet F, Piccirilli N, Tartarin F, Guilhot F, Chomel JC, Rousselot P, Nicolini FE, Ragot S, Gombert JM, Roy L, Herbelin A, Barbarin A.   +14 more
europepmc   +1 more source

Defining CP-CML patient subsets associated with poor imatinib uptake and response.

, 2014
Dale B. Watkins
openalex   +1 more source

Pathway‐Informed Machine Learning Identifies Genetic Predictors of High‐Dose Methotrexate‐Induced Mucositis in Pediatric Acute Lymphoblastic Leukemia

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 447-456, February 2026.
High‐dose methotrexate for pediatric cancer treatment is frequently associated with mucositis, which can lead to delayed or discontinued treatment and impact survival. While individual genetic variants have been implicated, the cumulative impact of genetic variation within relevant biological pathways remains unexplored.
Xiao Yu Cindy Zhang, Erika N. Scott, Hedy Maagdenberg, Alice Man, Kathy H. Li, S. Rod Rassekh, Bruce C. Carleton, Colin J. D. Ross, Wyeth W. Wasserman, Catrina M. Loucks   +9 more
wiley   +1 more source

Early <i>BCR::ABL1</i> Reduction as a Predictor of Deep Molecular Response in Pediatric Chronic-Phase Chronic Myeloid Leukemia. [PDF]

Cancers (Basel)
Wang X, An W, Liu C, Zhang B, Chen Y, Wan Y, Li X, Liu L, Liu F, Zhang L, Zou Y, Chen X, Chen Y, Guo Y, Hu T, Zhang Y, Zhu X, Yang W.   +17 more
europepmc   +1 more source

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source

Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia. [PDF]

Front Cell Dev Biol
Tiedemann L, Gorantla SP, Ahlf P, Schmidt LS, Pott C, Litterst M, Waetzig V, Nagel I, Ruemenapp J, von Bubnoff N, Cascorbi I, Kaehler M.   +11 more
europepmc   +1 more source